PDEX
Pro-Dex, Inc.44.70
+0.90+2.05%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
146.62MP/E (TTM)
13.46Basic EPS (TTM)
3.32Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
10-K
FY2025 results
Pro-Dex's FY2025 sales surged 24% to $66.6M, propelled by a 29% jump in medical devices to $47.7M, with orthopedic revenue up 42% y/y to $33.5M on the next-gen handpiece launch, while repairs grew 13% to $18.6M amid legacy enhancements. Yet Q4 stumbled as a customer shipment hold pinched momentum, though resumption late-quarter signals rebound; gross margins expanded to 29% from 27%, fueled by volume despite $2.5M under-absorption drag. Net income soared to $9.0M from $2.1M, aided by $1.5M unrealized investment gains, with diluted EPS at $2.67 on 3.36M shares. Backlog ballooned to $50.4M, liquidity solid at $32.7M working capital plus $7.3M revolver room, while $3.5M buybacks trimmed shares. Q4 faltered, but orders accelerate.
8-K
Pro-Dex FY2025 sales up 24%
Pro-Dex reported fiscal 2025 results on September 4, 2025, with net sales surging 24% to $66.6 million, driven by $12.0 million in next-generation handpiece sales to its largest customer, boosting operating income 49% to $10.7 million despite Q4 margin compression to 20% from tariff costs and product mix shifts. Net income jumped to $9.0 million, or $2.67 per diluted share, aided by $1.5 million in unrealized investment gains versus prior-year losses. Backlog hit $50.4 million. Fiscal 2026 growth looks solid.
IPO
Website
Employees
Sector
Industry
APYX
Apyx Medical Corporation
3.72-0.07
BDX
Becton, Dickinson and Company
196.39-3.70
ECIA
Encision, Inc.
0.15+0.00
IRIX
IRIDEX Corporation
1.00+0.02
ISRG
Intuitive Surgical, Inc.
554.58-4.94
PLSE
Pulse Biosciences, Inc
14.23+0.10
PRCT
PROCEPT BioRobotics Corporation
35.66-0.44
PROF
Profound Medical Corp.
7.55-0.14
RMD
ResMed Inc.
247.34-5.73
STXS
Stereotaxis, Inc.
2.38+0.06